BSE Live
Mar 30, 16:01Prev. Close
1583.65
Open Price
1602.70
Bid Price (Qty.)
1555.00 (5)
Offer Price (Qty.)
1620.00 (2)
NSE Live
Mar 30, 15:58Prev. Close
1586.00
Open Price
1594.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1601.20 (1)
| Key Financial Ratios of Ipca Laboratories (in Rs. Cr.) | Mar 05 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 29.63 | |
| Diluted EPS (Rs.) | 29.63 | |
| Cash EPS (Rs.) | 37.01 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 130.41 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 130.41 | |
| Revenue from Operations/Share (Rs.) | 284.10 | |
| PBDIT/Share (Rs.) | 48.69 | |
| PBIT/Share (Rs.) | 41.00 | |
| PBT/Share (Rs.) | 37.65 | |
| Net Profit/Share (Rs.) | 29.31 | |
| NP After MI And SOA / Share (Rs.) | 29.63 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 17.14 | |
| PBIT Margin (%) | 14.43 | |
| PBT Margin (%) | 13.25 | |
| Net Profit Margin (%) | 10.31 | |
| NP After MI And SOA Margin (%) | 10.43 | |
| Return on Networth/Equity (%) | 22.72 | |
| Return on Capital Employed (%) | 12.55 | |
| Return on Assets (%) | 10.77 | |
| Total Debt/Equity (X) | 0.68 | |
| Asset Turnover Ratio (%) | 103.28 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 3.70 | |
| Quick Ratio (X) | 1.86 | |
| Inventory Turnover Ratio (X) | 3.96 | |
| Dividend Payout Ratio (NP) (%) | 18.55 | |
| Dividend Payout Ratio (CP) (%) | 14.73 | |
| Earnings Retention Ratio (%) | 81.45 | |
| Cash Earnings Retention Ratio (%) | 85.27 | |
| Coverage Ratios | ||
| Interest Coverage Ratios (%) | 12.21 | |
| Interest Coverage Ratios (Post Tax) (%) | 12.21 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 967.98 | |
| EV/Net Operating Revenue (X) | 1.36 | |
| EV/EBITDA (X) | 7.95 | |
| MarketCap/Net Operating Revenue (X) | 1.06 | |
| Retention Ratios (%) | 81.44 | |
| Price/BV (X) | 2.31 | |
| Price/Net Operating Revenue | 1.06 | |
| Earnings Yield | 0.10 |
31.03.2026
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
18.02.2026
Buy Ipca Laboratories; target of Rs 1710: Prabhudas Lilladher
17.02.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
31.03.2026
31.03.2026
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth